26.26

3.06% -0.83

After Hours: 26.26

Pacira Biosciences Inc (PCRX)

Overview News Price History Option Chain Financials Discussions Forecast

Pacira Biosciences Inc stock is traded at $26.26, with a volume of 909.87K. It is down -3.06% in the last 24 hours and up +40.96% over the past month. Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

Previous Close:

$27.09

Open:

$27.17

24h Volume:

909.87K

Relative Volume:

1.18

Market Cap:

$1.21B

Revenue:

$681.75M

Net Income/Loss:

$70.47M

P/E Ratio:

18.11

EPS:

1.45

Net Cash Flow:

$173.19M

1W Performance:

+0.08%

1M Performance:

+40.96%

6M Performance:

+21.52%

1Y Performance:

-14.68%

1-Day Range:

$26.18

$27.17

1-Week Range:

$25.06

$27.17

52-Week Range:

$11.16

$31.67

Pacira Biosciences Inc Stock (PCRX) Company Profile

Name

Pacira Biosciences Inc

Sector

Healthcare (1177)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

813-553-6680

Address

5401 WEST KENNEDY BOULEVARD, TAMPA, NJ

Employee

712

Twitter

Next Earnings Date

2024-11-06

Latest SEC Filings

PCRX's Discussions on Twitter

Compare PCRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PCRX Pacira Biosciences Inc	26.26	1.21B	681.75M	70.47M	173.19M	1.45
ZTS Zoetis Inc	174.12	78.56B	9.15B	2.43B	2.31B	5.32
TAK Takeda Pharmaceutical Co Adr	13.61	43.15B	30.25B	1.37B	5.08B	0.4257
HLN Haleon Plc Adr	9.51	43.00B	14.26B	1.55B	0	0.3383
TEVA Teva Pharmaceutical Industries Ltd Adr	17.29	19.59B	16.54B	-1.64B	749.00M	-1.45
NBIX Neurocrine Biosciences Inc	150.51	15.24B	2.24B	385.90M	440.10M	3.73

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-25	Upgrade	Truist	Sell → Hold
Aug-13-24	Downgrade	Truist	Buy → Sell
Aug-12-24	Downgrade	JP Morgan	Overweight → Underweight
Aug-12-24	Downgrade	Piper Sandler	Overweight → Neutral
Aug-12-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Aug-12-24	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-03-24	Downgrade	Barclays	Overweight → Equal Weight
Mar-07-24	Resumed	JP Morgan	Overweight
Dec-20-23	Initiated	Raymond James	Outperform
Aug-03-23	Upgrade	TD Cowen	Market Perform → Outperform
Jan-31-23	Resumed	Wedbush	Outperform
Oct-21-22	Resumed	Jefferies	Buy
Jan-03-22	Resumed	JP Morgan	Overweight
Jul-26-21	Upgrade	JP Morgan	Neutral → Overweight
Apr-21-21	Resumed	JP Morgan	Neutral
Apr-09-21	Initiated	Berenberg	Buy
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Feb-11-21	Downgrade	Northland Capital	Outperform → Market Perform
Jan-21-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Sep-21-20	Upgrade	Northland Capital	Market Perform → Outperform
Jul-06-20	Reiterated	Needham	Buy
May-27-20	Initiated	Guggenheim	Neutral
Apr-07-20	Initiated	Northland Capital	Outperform
Mar-20-20	Upgrade	SVB Leerink	Mkt Perform → Outperform
Feb-24-20	Reiterated	H.C. Wainwright	Buy
Jan-24-20	Initiated	SunTrust	Buy
Jan-23-20	Initiated	SunTrust	Buy
Nov-06-19	Initiated	BTIG Research	Buy
Jun-11-19	Initiated	Barclays	Overweight
May-06-19	Upgrade	Mizuho	Underperform → Neutral
May-02-19	Upgrade	Stifel	Sell → Hold
Feb-01-19	Downgrade	Mizuho	Neutral → Underperform
Aug-06-18	Downgrade	BofA/Merrill	Buy → Neutral
Apr-09-18	Reiterated	H.C. Wainwright	Buy
Mar-21-18	Reiterated	Mizuho	Neutral
Feb-16-18	Downgrade	Needham	Buy → Hold
Jan-19-18	Initiated	Seaport Global Securities	Buy
Jan-04-18	Reiterated	Canaccord Genuity	Buy
Jan-03-18	Initiated	Leerink Partners	Mkt Perform

View All

Pacira Biosciences Inc Stock (PCRX) Latest News

Feb 06, 2025

Class Action Filed Against Pacira BioSciences, Inc. (PCRX) Seeking Recovery for Investors – Contact The Gross Law Firm - GlobeNewswire Inc.

Feb 06, 2025

PCRXPacira BioSciences, Inc. Latest Stock News & Market Updates - StockTitan

Feb 06, 2025

Is Pacira BioSciences Inc (PCRX) a good investment opportunity? - US Post News

Feb 06, 2025

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Feb 06, 2025

Feb 05, 2025

Pacira BioSciences, Inc. Stock News: Shareholder Rights Law Firm Robbins LLP Encourages PCRX Stockholders with Large Losses to Contact the Firm to Learn About Their Rights in Connection with the Class Action - PR Newswire

Feb 05, 2025

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF - The Bakersfield Californian

Feb 05, 2025

PACIRA BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS - GlobeNewswire

Feb 05, 2025

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Pacira BioSciences, Inc. Investors to - The Bakersfield Californian

Feb 05, 2025

Should You Buy Pacira (PCRX) After Golden Cross? - Zacks Investment Research

Feb 05, 2025

Pacira BioSciences, Inc. (NASDAQ:PCRX) Holdings Lifted by Gagnon Securities LLC - MarketBeat

Feb 05, 2025

The Recovery Playbook: Non-Opioid Pain Management Options After Surgery - NOLA.com

Feb 05, 2025

PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA - GlobeNewswire

Feb 05, 2025

Feb 04, 2025

PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - GlobeNewswire Inc.

Feb 04, 2025

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Pacira Biosciences, Inc. of Class Action Lawsuit and Upcoming DeadlinesPCRX - PR Newswire

Feb 04, 2025

Lowey Dannenberg Notifies Pacira Biosciences, Inc. - GlobeNewswire

Feb 04, 2025

Upward Trajectory: Pacira BioSciences Inc (PCRX) Posts a Slidee, Closing at 25.75 - The Dwinnex

Feb 04, 2025

Views of Wall Street’s Leading Experts on Pacira BioSciences Inc - SETE News

Feb 04, 2025

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pacira - GlobeNewswire

Feb 04, 2025

IMPORTANT NOTICE: IF YOUR FINANCIAL ADVISOR RECOMMENDED PACIRA BIOSCIENCES INVESTMENTS PLEASE CONTACT KT LAW - EIN News

Feb 04, 2025